Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Treatment outcomes for older patients with acute myeloid leukemia (AML) have remained dismal. This randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy compared low-dose cytarabine (LDAC) with or without volasertib, a highly potent and selective inhibitor...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Döhner, Hartmut, Lübbert, Michael, Fiedler, Walter, Fouillard, Loic, Haaland, Alf, Brandwein, Joseph M., Lepretre, Stephane, Reman, Oumedaly, Turlure, Pascal, Ottmann, Oliver G., Müller-Tidow, Carsten, Krämer, Alwin, Raffoux, Emmanuel, Döhner, Konstanze, Schlenk, Richard F., Voss, Florian, Taube, Tillmann, Fritsch, Holger, Maertens, Johan
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2014
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148765/
https://ncbi.nlm.nih.gov/pubmed/25006120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-03-560557
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki